Wolfgang Tilgen – författare

The last decade has seen a renaissance of the concept of individualized chemotherapy in oncology, markedly stimulated by the development of new in vitro chemosensitivity assays. The clinical utility of drug response assays has been evaluated in clinical trials and the results suggest that assay-assisted therapy selection may improve survival as well as economic outcomes. This volume comprises the proceedings of the first Symposium of the International Society for Chemosensitivity Testing in Oncology, ISCO-1, held in Homburg/Saar, Germany, in September 2001. The topics include: new in vitro drug-testing methods, tumor chemosensitivity assays, and the clinical relevance of assay-directed therapy.

Over the past 50 years many in vitro and in vivo drug response assay systems have been developed to determine the potential - tivity of chemotherapy agents. The idea was to eliminate ineffective agents and unnecessary toxic treatment while selecting drugs active in vitro or in the mouse model that might increase the probability of response in the patient. None of these test models, however, achieved routine clinical application in the past. This might be at least in part - lated to large discrepancies that were described between the s- cess rate of the assay systems and the clinical benefit in cancer - tients. The heterogeneity of chemosensitivity that exists between different tumors as well as between individual tumor lesions may be one explanation for these findings. Furthermore, different assay end points such as proliferation, metabolism, and vitality were - veloped to evaluate the effects of cytostatic drugs on tumor cells, and these might be related to the differing results. However, knowledge about procedures for assay-assisted treatment selection has increased rapidly within the past few years, and several studies suggest that test-directed chemotherapy selection now may - prove response rates and survival in various types of tumors. The International Society for Chemosensitivity Testing in - cology (ISCO) was founded to promote, coordinate, and improve clinical and laboratory research in the field of predictive drug te- ing in human tumor cells.

Die malignen Hauttumoren und die Präkanzerosen der Haut werden umfassend auch unter Einschluß der seltenen Tumoren dargestellt. Im Mittelpunkt steht dabei die histologische Diagnosesicherung. Daneben beschreibt das Buch weitere diagnostische Techniken einschließlich der sonographischen Verfahren und der Positronenemissionstomographie in ihrem derzeitigen Stellenwert. Die prognostische Wertigkeit und die Stadieneinteilung aller Tumoren wird behandelt. Der Hauptschwerpunkt liegt auf der Therapie der Hauttumoren. Die operative Therapie ist dabei genauso ausführlich berücksichtigt wie die medikamentöse Therapie einschließlich der Chemotherapeutika und Zytokine sowie die supportiven Therapien. Ein Standardwerk, das dem Leser aktuelles Wissen und genaue Anleitung für sein praktisches Vorgehen bietet.